Bibliografisk note

Funding Information:
A. B. Schmid receives grant funding from charities (Wellcome Trust, Medical Research Foundation, Versus Arthritis), government (UKRI, NIHR), and industry (ONO pharmaceutical). She receives lecture fees for postgraduate teaching in peripheral neuropathies and neuropathic pain. B. Tampin receives grant funding from the Sir Charles Gairdner Hospital and Osborne Park Health Care Group Research Advisory Committee and the Charlies Foundation for Research. H. Slater receives grant funding from the Australian Government (Commonwealth), the NH&MRC (MRFF), and Government of WA, Department of Health. R. Baron receives grant support from EU Projects: “Europain” (115007). DOLORisk (633491). IMI Paincare (777500). German Federal Ministry of Education and Research (BMBF): Verbundprojekt: Frühdetektion von Schmerzchronifizierung (NoChro) (13GW0338C). German Research Network on Neuropathic Pain (01EM0903). Pfizer Pharma GmbH, Genzyme GmbH, Grünenthal GmbH, Mundipharma Research GmbH und Co. KG., Novartis Pharma GmbH, Alnylam Pharmaceuticals Inc., Zambon GmbH, Sanofi-Aventis Deutschland GmbH. He received speaker fees from Pfizer Pharma GmbH, Genzyme GmbH, Grünenthal GmbH, Mundipharma, Sanofi Pasteur, Medtronic Inc. Neuromodulation, Eisai Co.Ltd., Lilly GmbH, Boehringer Ingel-heim Pharma GmbH & Co. KG, Astellas Pharma GmbH, Desitin Arzneimittel GmbH, Teva GmbH, Bayer-Schering, MSD GmbH, Seqirus Australia Pty. Ltd, Novartis Pharma GmbH, TAD Pharma GmbH, Grünenthal SA Portugal, Sanofi-Aventis Deutschland GmbH, Agentur Brigitte Süss, Grünenthal Pharma AG Schweiz, Grünenthal B.V. Niederlande, Evapharma, Takeda Pharmaceuticals International AG Schweiz, Ology Medical Education Netherlands. Ralf Baron received consultancy fees from Pfizer Pharma GmbH, Genzyme GmbH, Grünenthal GmbH, Mundipharma Research GmbH und Co. KG, Allergan, Sanofi Pasteur, Medtronic, Eisai, Lilly GmbH, Boehringer Ingelheim Pharma GmbH&Co.KG, Astellas Pharma GmbH, Novartis Pharma GmbH, Bristol-Myers Squibb, Biogenidec, AstraZeneca GmbH, Merck, Abbvie, Daiichi Sankyo, Glenmark Pharmaceuticals S.A., Seqirus Australia Pty. Ltd, Teva Pharmaceuticals Europe Niederlande, Teva GmbH, Genentech, Mundipharma International Ltd. UK, Astellas Pharma Ltd. UK, Galapagos NV, Kyowa Kirin GmbH, Vertex Pharmaceuticals Inc., Biotest AG, Celgene GmbH, Desitin Arzneimittel GmbH, Regeneron Pharmaceuticals Inc., Theranexus DSV CEA Frankreich, Abbott Pro-ducts Operations AG Schweiz, Bayer AG, Grünenthal Pharma AG Schweiz, Mundipharma Research Ltd. UK, Akcea Therapeutics Germany GmbH, Asahi Kasei Pharma Corporation, AbbVie Deutschland GmbH & Co. KG, Air Liquide Sante Inter-national Frankreich, Alnylam Germany GmbH, Lateral Pharma Pty Ltd, Hexal AG, An-gelini, Janssen, SIMR Biotech Pty Ltd Australien, Confo Therapeutics N. V. Belgium. N. B. Finnerup Outside the submitted work, NBF reports personal fees from Almirall, NeuroPN, Novartis Pharma, Vertex, and Nanobiotix and has undertaken consultancy work for Aarhus University for Biogen, Merz, and Confo Therapeutics, outside the submitted work and has received a grant from IMI2PainCare an EU IMI 2 (Innovative Medicines Initiative) public–private consortium and the companies involved are: Grünenthal, Bayer, Eli Lilly, Esteve, and Teva, outside the submitted work. P. Hansson declares no conflict of interest. K. Konstantinou declares no conflict of interest. C. Lin declares no conflict of interest. C. Price declares no conflict of interest. B. H. Smith was lead clinician for Chronic Pain for the Scottish Government (2014-2021) and receives grant funding from the Scottish Government, Eli Lilly, and UKRI/Versus Arthritis (not directly related to this work). A. Hietaharju received payment for lectures from Pfizer, Teva, Sanofi, and Lundbeck. Aki Hietaharju was the Chair of the NeuPSIG Executive Committee (2020-2022). J. Markman receives grant support from the National Institutes of Health. J. Markman received consultancy fees from Grunenthal, Merck AG, Eliem, Pfizer, Tremeau, Swan Bio, Nektar, Editas, Grunenthal, Biogen, Lilly, and Lateral Pharma. John Markman has served on Data Safety Monitoring Boards for Regenacy, Tonix, and Novartis pharmaceuticals. John Markman has equity in Yellowblack corporation and has served on the boards of Flowonix Corporation and the North American Neuromodulation Society.

Funding Information:
A. B. Schmid is supported by a Wellcome Trust Clinical Career Development Fellowship (222101/Z/20/Z), the Medical Research Foundation (Emerging Leaders Prize, MRF-160-0013-ELP-SCHM-C0842), and the National Institute for Health Research (NIHR) Oxford Health Biomedical Research Centre (BRC). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. B. Tampin receives funding from a Sir Charles Gairdner Hospital and Osborne Park Health Care Group Research Advisory Committee Grant and the Charlies Foundation for Research. C.-W. Christine Lin is funded by a research fellowship from the National Health and Medical Research Council, Australia. N. B. Finnerup is funded by a research grant from the Lundbeck Foundation (R359-2020-2620). The other authors report no funding related to this work.

Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.